Exeliris Co. Ltd. and Lin Gang Laboratory have reported phosphatidylinositol 3-kinase α (PI3Kα) inhibitors that are potentially useful for the treatment of cancer.

Fortvita Biologics Inc. and Innovent Biologics (Hangzhou) Co. Ltd. have patented bispecific antibody-drug conjugates (ADCs) comprising a bispecific humanized monoclonal antibody targeting EGFR and hepatocyte growth factor receptors (HGFR; MET) linked to cytotoxic drugs reported to be useful for the treatment of cancer.

Alzecure Pharma AB has disclosed UDP-glucuronosyltransferase A1 (UGT1A1; UDPGT 1-1) inhibitors that are potentially useful for the treatment of Lewy body dementia, Creutzfeldt-Jakob disease, frontotemporal dementia, amyotrophic lateral sclerosis, traumatic brain injury, and Parkinson's, Alzheimer's and Huntington's disease, among others.

Innovstone Therapeutics Ltd. has synthesized cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors found to be potentially useful for the treatment of autoimmune diseases and cancer.

Betta Pharmaceuticals Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds consisting of a Von Hippel-Lindau-binding moiety coupled to a GTPase KRAS-targeting moiety through a linker acting as KRAS degradation inducers.

Bioray Pharmaceutical Co. Ltd. has prepared and tested new antibody-drug conjugates consisting of antibodies covalently linked to payloads. They are reported to be potentially useful for the treatment of cancer, infections, inflammatory and immunological disorders.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has patented new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of metabolic diseases.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged new antibody-drug conjugates comprising antibodies targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5; CEA; CD66e) covalently linked to a cytotoxic drug potentially useful for the treatment of colorectal cancer.

Zonsen Peplib Biotech Inc. has synthesized new peptide-drug conjugates comprising a glypican-3 (GPC3)-targeting peptide covalently linked to a payload potentially useful for the treatment of cancer.

A recent Beone Medicines I GmbH and Beone Pharmaceutical (Suzhou) Co. Ltd. patent describes new 4-substituted fused bicyclic heteroaryl derivatives acting as Kelch-like ECH-associated protein 1 (Keap1)/CUL3 interaction inducers reported to be useful for the treatment of cancer.